Tag:
GW Pharma
Latest Headlines
Latest Headlines
GW prices Sativex for MS pain
GW Pharmaceuticals wasted no time preparing to launch its newly-approved Sativex for MS patients . The UK developer says that it will sell the cannabis-based pain therapy for $14 a day. The Wall
GW Pharma's cannabis drug Sativex wins landmark approval
After a long and complex R&D odyssey, GW Pharmaceuticals (GWP) has finally won UK approval for Sativex, a drug derived from cannabis that can now be used to treat spasticity in MS patients. GW
Bad trial design faulted for GW's Phase III failure
Blindsided by a big placebo effect, GW Pharma says its lead therapy Sativex  for pain narrowly missed hitting the goal of statistically
